Business Context and Reporting Period
This Form 8-K is a Current Report filed by Organovo Holdings, Inc. (trading symbol: ONVO) on December 23, 2024. The report details significant changes in executive leadership, specifically the resignation of the former President and Chief Financial Officer (CFO) and the appointment of a successor effective December 30, 2024.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and related contractual arrangements.
Material Changes
- Resignation: Tomas Hess, the former President, CFO, and Principal Financial Officer, resigned effective December 24, 2024, to pursue retirement. The resignation is not related to any disagreement with the Company regarding accounting or financial policies.
- Appointment: Norman Staskey was appointed as President, CFO, and Principal Financial Officer, effective December 30, 2024.
- Compensation Structure: Mr. Staskey will provide services on a part-time basis through Danforth Advisors, LLC. The Company will pay Danforth $450.00 per hour for Mr. Staskey's services under an amended Consulting Agreement.
Outlook, Risks, and Management Commentary
Management views Mr. Staskey's appointment as a strategic addition, citing his experience in mergers and acquisitions (M&A) as particularly relevant to the Company's interest in potential strategic transactions with other pharmaceutical companies. The Company maintains full-time internal senior finance staff to ensure operational continuity alongside Mr. Staskey's part-time role. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the terms of the amended Consulting Agreement (Exhibit 10.2) regarding the $450/hour rate and scope of services.
- Confirm the transition timeline between Mr. Hess's resignation (Dec 24) and Mr. Staskey's start date (Dec 30).
- Review Mr. Staskey's background in M&A to assess alignment with the Company's stated strategic interests.
- Note that the filing text does not provide updated financial statements or liquidity positions.